Memorial Sloan Kettering Cancer Center

- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1884-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.mskcc.org
Clinical Trials
1.9k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1442 trials with phase data)• Click on a phase to view related trials
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
- Conditions
- Blood CancerLymphomaLeukemiaMyeloma
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT07052916
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States
A Study of Surgery and Radiotherapy in People With Breast Cancer
- Conditions
- Metastatic Breast CancerHER2-positive Breast Cancer
- Interventions
- Drug: Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugsProcedure: Lumpectomy or mastectomyRadiation: Radiotherapy
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 162
- Registration Number
- NCT07053085
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
A Study of Revaree Plus in People With Breast Cancer
- Conditions
- Breast CancerStage 0 Breast CancerStage I Breast CancerStage II Breast CancerStage III Breast CancerStage 0 Breast CarcinomaStage II Breast CarcinomaStage III Breast CarcinomaHormone-receptor-positive Breast CancerHormone Receptor Positive Breast Carcinoma
- Interventions
- Drug: Revaree Plus
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT07042581
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Consent Only), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT07030699
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors
- Conditions
- SurvivorshipRecurrentRecurrenceCancerRemission
- First Posted Date
- 2025-06-22
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 1000
- Registration Number
- NCT07030686
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 374
- Next
News
YIV-906 Shows Promising Results in Phase 2b Trial for Advanced Hepatocellular Carcinoma with Hepatitis B
Yiviva's Phase 2b study demonstrated that YIV-906 plus sorafenib significantly improved median overall survival to 14.3 months versus 7.5 months with sorafenib alone in HBV-positive advanced hepatocellular carcinoma patients.
QBiotics' Tigilanol Tiglate Achieves 80% Response Rate in Soft Tissue Sarcoma Phase IIa Trial
QBiotics reported an 80% objective response rate in Stage 1 of its Phase IIa trial evaluating tigilanol tiglate in 10 patients with advanced soft tissue sarcoma.
NCT/UCC Dresden Launches Phase 2 Trial of Personalized mRNA Vaccine for Pancreatic Cancer
NCT/UCC Dresden becomes the only site in Saxony to offer patients access to BioNTech and Genentech's personalized mRNA vaccine Autogene Cevumeran for pancreatic cancer treatment.
Liso-cel Achieves 95.5% Response Rate in Relapsed/Refractory Marginal Zone Lymphoma
Lisocabtagene maraleucel (liso-cel) demonstrated a 95.5% overall response rate and 62.1% complete response rate in 66 patients with relapsed/refractory marginal zone lymphoma in the TRANSCEND FL trial.
Curadev and Memorial Sloan Kettering Expand Collaboration to Advance Novel STING Agonist CRD3874-SI
Curadev Pharma and Memorial Sloan Kettering Cancer Center are expanding their collaboration through MSK's Therapeutics Accelerator program to advance development of CRD3874-SI, a first-in-class allosteric STING agonist.
ImPact Biotech's Padeliporfin VTP Therapy Enables Surgical Resection in Previously Inoperable Pancreatic Cancer Patient
ImPact Biotech's first patient in a Phase 1 trial of Padeliporfin VTP therapy for locally advanced pancreatic ductal adenocarcinoma successfully underwent surgical resection after being initially deemed inoperable.
Minerva Biotechnologies Advances MUC1*-Targeted CAR-T Therapy with 1XX Mutations for Solid Tumors
Minerva Biotechnologies published research demonstrating that MUC1*-targeted CAR-T cells with 1XX mutations show increased persistence and ability to kill low antigen-expressing cancer cells in animal models.
Juri Biosciences Secures Global Rights to KLK2-Targeted T-Cell Engager for Metastatic Prostate Cancer in $210M Deal
Juri Biosciences, a TCG Labs Soleil portfolio company, has entered into a worldwide licensing agreement with EpimAb Biotherapeutics for exclusive global rights to a KLK2-targeted T-cell engager for metastatic prostate cancer treatment.
Pharmacists Take Central Role in Managing Novel Cancer Therapies as CAR-T and Bispecific Antibodies Transform Treatment Landscape
Pharmacists have evolved from traditional dispensing roles to comprehensive patient management in cancer care, particularly with novel therapies like CAR-T cell therapy and bispecific antibodies.
New Genetic Findings Challenge Traditional Understanding of Coats' Disease
Research led by Dr. David Abramson reveals that Coats' disease, traditionally considered unilateral, shows bilateral involvement when examined with fluorescein angiography, challenging long-held clinical beliefs.